Eli Lilly and AstraZeneca scrap Alzheimer’s drug tests
Independent monitoring committee found medicine unlikely to meet its goals
Eli Lilly & Co: “We are deeply disappointed for the millions suffering from this devastating disease.” Photograph: Simone Baribeau/Bloomberg
Eli Lilly and AstraZeneca ended two late-stage trials of an experimental drug for Alzheimer’s disease after the treatment failed to show any signs of working, adding to a litany of disappointments for the illness.
An independent data-monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease, the companies said on Tuesday. There were no safety concerns, they said.
Like several others that failed, such as Merck’s verubecestat, the drug targeted a protein called amyloid, thought to be a cause of the disease. The class of medicines known as BACE inhibitors operate before the amyloid has formed into deposits, called plaques. Many researchers now believe that administering drugs after amyloid has built up in the brain may come too late to affect Alzheimer’s progress.
“The complexity of Alzheimer’s disease poses one of the most difficult medical challenges of our time, and we are deeply disappointed for the millions suffering from this devastating disease,” said Daniel Skovronsky, president of Lilly Research Labs.
The decision to end the trials won’t have a material financial impact on AstraZeneca, and its guidance for this year remains unchanged, the Cambridge-based company said in a separate statement. Lilly doesn’t anticipate significant costs associated with the end of the studies and reaffirmed its outlook for 2018 and the remainder of the decade.
By one count, more than 190 Alzheimer drugs have failed in trials.
Despite billions of dollars spent by the drug industry searching for a treatment, no medicines have yet been developed that slow the progress of Alzheimer’s. The failures have left analysts pessimistic about many of the experimental medicines that companies are working on. Roger Franklin of Liberum Capital, said he, like most analysts, had forecast no revenue from lanabecestat for AstraZeneca.
“This is absolutely no surprise to us given failures by others with this so-called BACE inhibitor mechanism and the track record of late-stage Alzheimer’s studies more generally,” he wrote in a report on Tuesday.
A new approach centres on targeting the protein tau, another degenerative process identified in the brain of Alzheimer’s patients. Tau protein forms into tangles, which start in the areas of the brain important for memory. Lilly, Merck, AbbVie, Biogen and Roche Holding AG are among the drugmakers pursuing that route.
AstraZeneca shares fell 0.9 percent in London, trading at 5,322p this morning. Lilly closed at $85.86 Monday in New York.